查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
血液学恶性肿瘤检测市场 - 2017-2027年全球行业规模、份额、趋势、机会和预测，按成分、技术、治疗指征、终端用户、公司和地区分类
市场调查报告书
商品编码
1289650

血液学恶性肿瘤检测市场 - 2017-2027年全球行业规模、份额、趋势、机会和预测，按成分、技术、治疗指征、终端用户、公司和地区分类

Hematologic Malignancies Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Component, By Technique, By Therapeutic Indication, By End User, By company and By Region
出版日期: | 出版商: TechSci Research | 英文 114 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

在2023-2027年的预测期内，全球血液恶性肿瘤检测市场预计将出现令人瞩目的增长。主要因素，包括血癌发生率的增加和技术的广泛发展，正在推动市场的增长。血液学恶性肿瘤是影响血液、骨髓和淋巴结的癌症。白血病、淋巴瘤和骨髓瘤是血癌的常见类型。血液学恶性肿瘤检测是一种有助于诊断血癌的医学检测方法。支持市场增长的其他因素有：研发活动的增加，政府资金的增加，对个性化医疗的重视，患者和医疗专业人士意识的增加，老龄化人口的增加，无机增长战略的增加，产品推出的数量增加，以及新兴子市场的巨大潜力。

血液相关疾病的发生率不断增加

血液相关疾病，如白血病、淋巴瘤和骨髓瘤的发病率不断增加，正在推动全球市场的增长。根据美国癌症协会的数据，在美国，大约每3分钟就有一个人被诊断出患有白血病、淋巴瘤和骨髓瘤。由于患有血液病的病人数量增加，对血癌的早期检测和治疗的需求激增，从而促进了市场的增长。血癌是全球第五大最常见的恶性肿瘤，也是癌症死亡的第二个主要原因。例如，全球每年有30多万人被诊断为白血病，40多万人被诊断为淋巴瘤。

技术进步和研发活动的增加

医疗保健领域新技术的发展正在推动市场的增长。越来越多地采用新的创新技术，如数字PCR、下一代测序、细胞遗传学和其他，正在加强市场的增长。这些发展有助于最大限度地减少治疗的成本和时间，提高人类生活质量。此外，研发活动的增加正在推动市场的增长。

越来越多地采用无机增长战略

越来越多的无机增长战略，如合并、收购、合作、伙伴关系，以及市场参与者推出越来越多的产品，正在推动市场的增长。例如，2021年，Natera公司和Personalis公司在个性化肿瘤学方面建立了伙伴关系，将Personalis公司的NeXT肿瘤分析和诊断产品与Natera公司的个性化ctDNA平台Signatera结合起来，用于治疗监测和分子残余疾病评估。同样，在2018年，雅培推出了融合了血液学系统的h系列，并在此后给临床实验室带来了众多变化。

可用的定制服务

利用给定的市场数据，TechSci Research根据公司的具体需求提供定制服务。该报告有以下定制选项：

公司信息

  • 对其他市场参与者（最多五个）的详细分析和简介。

目录

第一章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：COVID-19对全球血液学恶性肿瘤检测市场的影响

第五章：客户的声音

第六章：临床试验分析

第七章 ：全球血液学恶性肿瘤检测市场展望

  • 市场规模和预测
    • 按价值
  • 市场份额与预测
    • 按组件（试剂盒和服务）分类
    • 按技术分类（下一代测序（NGS）、聚合酶链式反应（PCR）、荧光原位杂交（FISH）、免疫组织化学（IHC）、其他）
    • 按治疗适应症（白血病、淋巴瘤、多发性骨髓瘤、骨髓增生性肿瘤、其他）
    • 按终端用户（医院和诊所、诊断实验室、学术和研究机构、其他）分类
    • 按公司分类（2021年）
    • 按地区分类
  • 市场地图

第八章：北美血液学恶性肿瘤检测市场展望

  • 市场规模和预测
    • 按价值分类
  • 市场份额与预测
    • 按组件（试剂盒和服务）分类
    • 按技术分类（下一代测序（NGS）、聚合酶链式反应（PCR）、荧光原位杂交（FISH）、免疫组织化学（IHC）、其他）
    • 按治疗适应症（白血病、淋巴瘤、多发性骨髓瘤、骨髓增生性肿瘤、其他）
    • 按终端用户（医院和诊所、诊断实验室、学术和研究机构、其他）分类
    • 按国家分类
  • 北美洲：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第九章：欧洲血液学恶性肿瘤检测市场展望

  • 市场规模和预测
    • 按价值计算
  • 市场份额与预测
    • 按组件（试剂盒和服务）分类
    • 按技术分类（下一代测序（NGS）、聚合酶链反应（PCR）、荧光原位杂交（FISH）、免疫组化（IHC）、其他）
    • 按治疗适应症（白血病、淋巴瘤、多发性骨髓瘤、骨髓增生性肿瘤、其他）
    • 按终端用户（医院和诊所、诊断实验室、学术和研究机构、其他）分类
    • 按国家分类
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 意大利
    • 西班牙

第十章：亚太地区血液学恶性肿瘤检测市场展望

  • 市场规模和预测
    • 按价值计算
  • 市场份额与预测
    • 按组件（试剂盒和服务）分类
    • 按技术分类（下一代测序（NGS）、聚合酶链式反应（PCR）、荧光原位杂交（FISH）、免疫组织化学（IHC）、其他）
    • 按治疗适应症（白血病、淋巴瘤、多发性骨髓瘤、骨髓增生性肿瘤、其他）
    • 按终端用户（医院和诊所、诊断实验室、学术和研究机构、其他）分类
    • 按国家分类
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳大利亚

第11章 ：南美血液学恶性肿瘤检测市场展望

  • 市场规模和预测
    • 按价值计算
  • 市场份额与预测
    • 按组件（试剂盒和服务）分类
    • 按技术分类（下一代测序（NGS）、聚合酶链反应（PCR）、荧光原位杂交（FISH）、免疫组化（IHC）、其他）
    • 按治疗适应症（白血病、淋巴瘤、多发性骨髓瘤、骨髓增生性肿瘤、其他）
    • 按终端用户（医院和诊所、诊断实验室、学术和研究机构、其他）分类
    • 按国家分类
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第十二章 ：中东和非洲血液学恶性肿瘤检测市场展望

  • 市场规模和预测
    • 按价值计算
  • 市场份额与预测
    • 按组件（试剂盒和服务）分类
    • 按技术分类（下一代测序（NGS）、聚合酶链反应（PCR）、荧光原位杂交（FISH）、免疫组化（IHC）、其他）
    • 按治疗适应症（白血病、淋巴瘤、多发性骨髓瘤、骨髓增生性肿瘤、其他）
    • 按终端用户（医院和诊所、诊断实验室、学术和研究机构、其他）分类
    • 按国家分类
  • MEA: 国家分析
    • 南非 血液学恶性肿瘤检测
    • 沙特阿拉伯 血液学恶性肿瘤检测
    • 阿联酋 血液学恶性肿瘤检测
    • 土耳其 血液学恶性肿瘤测试
    • 埃及 血液学恶性肿瘤检测

第十三章 ：市场动态

  • 驱动力
  • 挑战

第十四章：市场趋势与发展

第十五章 ：竞争格局

  • 阿博特实验室公司Asuragen Inc.生物瑞德实验室公司（Bio-Rad Laboratories, Inc.Adaptive Biotechnologies Corporation F.Hoffmann-La-Roche AG Illumina, Inc.ICON plc.Invitae Corporation Laboratory Corporation of America Holdings Invivoscribe, Inc.

第16章 ：战略建议

简介目录
Product Code: 13004

The global hematologic malignancies testing market is anticipated to observe impressive growth during the forecast period 2023-2027. The major factors, including growing occurrences of blood cancer and extensive development in technology, are fueling the growth of the market. Hematologic malignancies are cancers that affect the blood, bone marrow, and lymph nodes. Leukemia, lymphoma, and myeloma are the common types of blood cancer. Hematologic malignancies testing is a medical testing method that helps to diagnose blood cancer. The other factors supporting the market's growth are a rise in R&D activities, increasing favorable government funding, rising emphasis on personalized medicine, increasing awareness among patients and healthcare professionals, rise in aging population base, growing adoption of inorganic growth strategies, an increasing number of product launches, and immense potential for emerging submarkets.

Increasing Occurrence of Blood-Related Disorders

The growing incidences of blood-related disorders, such as leukemia, lymphoma, and myeloma, are bolstering the growth of the market globally. According to the American Cancer Society, in the United States, around every 3 minutes, a person is diagnosed with leukemia, lymphoma, and myeloma. Owing to the rise in the number of patients who have hematologic cancer, the surge in the need for early detection and treatment of blood cancers is augmenting the growth of the market. Blood cancers are the fifth most common malignancy across the world and the second primary reason for cancer death. For instance, more than 300,000 people are diagnosed yearly with leukemia and 400,000 with lymphoma across the globe.

Technological Advancements and Rise in R&D Activities

The evolution of new technologies in the healthcare sector is surging the growth of the market. The increasing adoption of new innovative technologies, such as digital PCR, next-generation sequencing, cytogenetics, and others, is strengthening the growth of the market. The developments are helping to minimize the cost and time of treatment and improve the quality of human life. Moreover, the rise in R&D activities is propelling the growth of the market.

Increasing Adoption of Inorganic Growth Strategies

Growing inorganic growth strategies such as mergers, acquisitions, collaborations, partnerships, and an increasing number of product launches by market players are bolstering the growth of the market. For instance, in 2021, Natera, Inc., and Personalis, Inc. partnered in personalized oncology by coupling Personalis' NeXT tumor profiling and diagnostic products with Natera's personalized ctDNA platform Signatera for treatment monitoring and molecular residual disease assessment. Similarly, in 2018, Abbott launched an h-series incorporating a hematology system and has brought numerous changes in the clinical laboratories since then.

Market Segmentation

The global hematologic malignancies testing market is segmented into component, technique, therapeutic indication, end user, and company. Based on components, the market is divided into kits and services. Based on kits, the market is further divided into gene panels, molecular clonality testing, translocation testing, mutation testing, and others. Based on technique, the market is divided into next-generation sequencing (NGS), polymerase chain reaction (PCR), fluorescence in-situ hybridization (FISH), immunohistochemistry (IHC), and others. Based on therapeutic indication, the market is divided into leukemia, lymphoma, multiple myeloma, myeloproliferative neoplasms, and others. Based on end-user, the market is divided into hospitals & clinics, diagnostic laboratories, academic & research institutions, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to rising incidences of blood cancers in the country.

Market Players

Abbott Laboratories, Inc., Asuragen Inc., Bio-Rad Laboratories, Inc., Adaptive Biotechnologies Corporation, F.Hoffmann-La-Roche AG, Illumina, Inc., ICON plc., Invitae Corporation, Laboratory Corporation of America Holdings, and Invivoscribe, Inc. are some of the leading companies operating in the market.

Report Scope

In this report, global hematologic malignancies testing market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hematologic Malignancies Testing Market, By Component:

  • Kits
    • Gene Panels
    • Molecular Clonality Testing
    • Translocation Testing
    • Mutation Testing
    • Others
  • Services

Hematologic Malignancies Testing Market, By Component:

  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Fluorescence In-Situ Hybridization (FISH)
  • Immunohistochemistry (IHC)
  • Others

Hematologic Malignancies Testing Market, By Therapeutic Indication:

  • Leukemia
  • Lymphoma
  • Multiple Myeloma
  • Myeloproliferative Neoplasms
  • Others

Hematologic Malignancies Testing Market, By End User:

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Academic & Research Institutions
  • Others

Hematologic Malignancies Testing Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Europe & CIS
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Egypt
    • Turkey

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Hematologic Malignancies Testing Market

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Hematologic Malignancies Testing Market

5. Voice of Customer

6. Clinical Trial Analysis

7. Global Hematologic Malignancies Testing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Component (Kits v/s Services)
      • 7.2.1.1. By Kits (Gene Panels, Molecular Clonality Testing, Translocation Testing, Mutation Testing, Others)
    • 7.2.2. By Technique (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
    • 7.2.3. By Therapeutic Indication (Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others)
    • 7.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Others)
    • 7.2.5. By Company (2021)
    • 7.2.6. By Region
  • 7.3. Market Map

8. North America Hematologic Malignancies Testing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Component (Kits v/s Services)
      • 8.2.1.1. By Kits (Gene Panels, Molecular Clonality Testing, Translocation Testing, Mutation Testing, Others)
    • 8.2.2. By Technique (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
    • 8.2.3. By Therapeutic Indication (Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others)
    • 8.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Others)
    • 8.2.5. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Hematologic Malignancies Testing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Component
        • 8.3.1.2.2. By Technique
        • 8.3.1.2.3. By Therapeutic Indication
        • 8.3.1.2.4. By End User
    • 8.3.2. Canada Hematologic Malignancies Testing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Component
        • 8.3.2.2.2. By Technique
        • 8.3.2.2.3. By Therapeutic Indication
        • 8.3.2.2.4. By End User
    • 8.3.3. Mexico Hematologic Malignancies Testing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Component
        • 8.3.3.2.2. By Technique
        • 8.3.3.2.3. By Therapeutic Indication
        • 8.3.3.2.4. By End User

9. Europe Hematologic Malignancies Testing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Component (Kits v/s Services)
      • 9.2.1.1. By Kits (Gene Panels, Molecular Clonality Testing, Translocation Testing, Mutation Testing, Others)
    • 9.2.2. By Technique (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
    • 9.2.3. By Therapeutic Indication (Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others)
    • 9.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Others)
    • 9.2.5. By Country
  • 9.3. Europe: Country Analysis
    • 9.3.1. France Hematologic Malignancies Testing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Component
        • 9.3.1.2.2. By Technique
        • 9.3.1.2.3. By Therapeutic Indication
        • 9.3.1.2.4. By End User
    • 9.3.2. Germany Hematologic Malignancies Testing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Component
        • 9.3.2.2.2. By Technique
        • 9.3.2.2.3. By Therapeutic Indication
        • 9.3.2.2.4. By End User
    • 9.3.3. United Kingdom Hematologic Malignancies Testing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Component
        • 9.3.3.2.2. By Technique
        • 9.3.3.2.3. By Therapeutic Indication
        • 9.3.3.2.4. By End User
    • 9.3.4. Italy Hematologic Malignancies Testing Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Component
        • 9.3.4.2.2. By Technique
        • 9.3.4.2.3. By Therapeutic Indication
        • 9.3.4.2.4. By End User
    • 9.3.5. Spain Hematologic Malignancies Testing Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Component
        • 9.3.5.2.2. By Technique
        • 9.3.5.2.3. By Therapeutic Indication
        • 9.3.5.2.4. By End User

10. Asia-Pacific Hematologic Malignancies Testing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Component (Kits v/s Services)
      • 10.2.1.1. By Kits (Gene Panels, Molecular Clonality Testing, Translocation Testing, Mutation Testing, Others)
    • 10.2.2. By Technique (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
    • 10.2.3. By Therapeutic Indication (Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others)
    • 10.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Others)
    • 10.2.5. By Country
  • 10.3. Asia-Pacific: Country Analysis
    • 10.3.1. China Hematologic Malignancies Testing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Component
        • 10.3.1.2.2. By Technique
        • 10.3.1.2.3. By Therapeutic Indication
        • 10.3.1.2.4. By End User
    • 10.3.2. India Hematologic Malignancies Testing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Component
        • 10.3.2.2.2. By Technique
        • 10.3.2.2.3. By Therapeutic Indication
        • 10.3.2.2.4. By End User
    • 10.3.3. Japan Hematologic Malignancies Testing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Component
        • 10.3.3.2.2. By Technique
        • 10.3.3.2.3. By Therapeutic Indication
        • 10.3.3.2.4. By End User
    • 10.3.4. South Korea Hematologic Malignancies Testing Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Component
        • 10.3.4.2.2. By Technique
        • 10.3.4.2.3. By Therapeutic Indication
        • 10.3.4.2.4. By End User
    • 10.3.5. Australia Hematologic Malignancies Testing Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Component
        • 10.3.5.2.2. By Technique
        • 10.3.5.2.3. By Therapeutic Indication
        • 10.3.5.2.4. By End User

11. South America Hematologic Malignancies Testing Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Component (Kits v/s Services)
      • 11.2.1.1. By Kits (Gene Panels, Molecular Clonality Testing, Translocation Testing, Mutation Testing, Others)
    • 11.2.2. By Technique (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
    • 11.2.3. By Therapeutic Indication (Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others)
    • 11.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Others)
    • 11.2.5. By Country
  • 11.3. South America: Country Analysis
    • 11.3.1. Brazil Hematologic Malignancies Testing Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Component
        • 11.3.1.2.2. By Technique
        • 11.3.1.2.3. By Therapeutic Indication
        • 11.3.1.2.4. By End User
    • 11.3.2. Argentina Hematologic Malignancies Testing Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Component
        • 11.3.2.2.2. By Technique
        • 11.3.2.2.3. By Therapeutic Indication
        • 11.3.2.2.4. By End User
    • 11.3.3. Colombia Hematologic Malignancies Testing Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Component
        • 11.3.3.2.2. By Technique
        • 11.3.3.2.3. By Therapeutic Indication
        • 11.3.3.2.4. By End User

12. Middle East and Africa Hematologic Malignancies Testing Market Outlook

  • 12.1. Market Size & Forecast
    • 12.1.1. By Value
  • 12.2. Market Share & Forecast
    • 12.2.1. By Component (Kits v/s Services)
      • 12.2.1.1. By Kits (Gene Panels, Molecular Clonality Testing, Translocation Testing, Mutation Testing, Others)
    • 12.2.2. By Technique (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
    • 12.2.3. By Therapeutic Indication (Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others)
    • 12.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Others)
    • 12.2.5. By Country
  • 12.3. MEA: Country Analysis
    • 12.3.1. South Africa Hematologic Malignancies Testing Market Outlook
      • 12.3.1.1. Market Size & Forecast
        • 12.3.1.1.1. By Value
      • 12.3.1.2. Market Share & Forecast
        • 12.3.1.2.1. By Component
        • 12.3.1.2.2. By Technique
        • 12.3.1.2.3. By Therapeutic Indication
        • 12.3.1.2.4. By End User
    • 12.3.2. Saudi Arabia Hematologic Malignancies Testing Market Outlook
      • 12.3.2.1. Market Size & Forecast
        • 12.3.2.1.1. By Value
      • 12.3.2.2. Market Share & Forecast
        • 12.3.2.2.1. By Component
        • 12.3.2.2.2. By Technique
        • 12.3.2.2.3. By Therapeutic Indication
        • 12.3.2.2.4. By End User
    • 12.3.3. UAE Hematologic Malignancies Testing Market Outlook
      • 12.3.3.1. Market Size & Forecast
        • 12.3.3.1.1. By Value
      • 12.3.3.2. Market Share & Forecast
        • 12.3.3.2.1. By Component
        • 12.3.3.2.2. By Technique
        • 12.3.3.2.3. By Therapeutic Indication
        • 12.3.3.2.4. By End User
    • 12.3.4. Turkey Hematologic Malignancies Testing Market Outlook
      • 12.3.4.1. Market Size & Forecast
        • 12.3.4.1.1. By Value
      • 12.3.4.2. Market Share & Forecast
        • 12.3.4.2.1. By Component
        • 12.3.4.2.2. By Technique
        • 12.3.4.2.3. By Therapeutic Indication
        • 12.3.4.2.4. By End User
    • 12.3.5. Egypt Hematologic Malignancies Testing Market Outlook
      • 12.3.5.1. Market Size & Forecast
        • 12.3.5.1.1. By Value
      • 12.3.5.2. Market Share & Forecast
        • 12.3.5.2.1. By Component
        • 12.3.5.2.2. By Technique
        • 12.3.5.2.3. By Therapeutic Indication
        • 12.3.5.2.4. By End User

13. Market Dynamics

  • 13.1. Drivers
  • 13.2. Challenges

14. Market Trends & Developments

15. Competitive Landscape

  • 15.1. Abbott Laboratories, Inc.
  • 15.2. Asuragen Inc.
  • 15.3. Bio-Rad Laboratories, Inc.
  • 15.4. Adaptive Biotechnologies Corporation
  • 15.5. F.Hoffmann-La-Roche AG
  • 15.6. Illumina, Inc.
  • 15.7. ICON plc.
  • 15.8. Invitae Corporation
  • 15.9. Laboratory Corporation of America Holdings
  • 15.10. Invivoscribe, Inc.

16. Strategic Recommendations